Allarity Therapeutics (NASDAQ:ALLR) Stock Price Crosses Above 50-Day Moving Average – What’s Next?

Allarity Therapeutics, Inc. (NASDAQ:ALLR)’s share price crossed above its 50-day moving average during trading on Tuesday. The stock has a 50-day moving average of $1.08 and traded as high as $1.13. Allarity Therapeutics shares last traded at $1.13, with a volume of 320,463 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Thursday, October 15th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $10.25.

Allarity Therapeutics Stock Performance

The stock has a market capitalization of $17.98 million, a PE ratio of -1.45 and a beta of 0.57. The firm’s 50 day moving average is $1.08 and its two-hundred day moving average is $1.22.

Allarity Therapeutics (NASDAQ:ALLR) last released its earnings results on Friday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.04. On average, analysts anticipate that Allarity Therapeutics, Inc. will post -0.80 EPS for the current year.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc (NASDAQ: ALLR) is a clinical-stage biotechnology company focused on developing personalized treatments for cancer. The company uses its Drug Response Predictor (DRP) technology to analyze patient and tumor characteristics and identify individuals who may be more likely to respond to specific drug candidates.

Allarity’s development programs have included stenoparib, also known as 2X-121, an orally administered PARP inhibitor being investigated for potential use in oncology.